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Over time, there has been increasing recognition of the 
importance of preservation of residual kidney function 
(RKF) in dialysis patients (1). The presence of RKF has 
been shown to contribute to the overall health and well-
being of dialysis patients including improved survival, better 
nutrition, and reduced inflammation (2-4). Compared 
to patients receiving peritoneal dialysis, the importance 
of RKF among patients receiving hemodialysis has been 
relatively less appreciated and mostly disregarded at the 
commencement of hemodialysis, given prior reports that 
RKF declines more rapidly following hemodialysis initiation 
(5,6). However, contrary to popular belief, rapid decline 
of RKF does not necessarily occur after transitioning 
to hemodialysis, although those who are receiving this 
modality may be at risk of RKF loss owing to potential 
intradialytic hypotension, nephrotoxic drugs, and co-
existing comorbidities (e.g., congestive heart failure) (7). 
Moreover, given growing evidence demonstrating robust 
associations between RKF and survival in hemodialysis 
patients,  preservation of RKF has become a valid 
therapeutic goal in this population (2,8).
Traditionally, the thrice-weekly hemodialysis start 
has been considered as the standard treatment regimen 
for initiation of therapy among incident hemodialysis 
patients regardless of their RKF. It is not clear, however, 
why dialysis should be “started” abruptly, as opposed to 
a gradual “transition” to dialysis, using approaches such 
as less frequent dialysis treatment including twice-weekly 
hemodialysis (9). In the English language, there are 
indeed fundamental differences in meaning between the 
terminology “start” vs. “transition” (see Figure 1). Based 
on the 2006 Kidney Disease Outcome Quality Initiative 
(KDOQI) Clinical Practice Guidelines, Guideline 4.3.2., 
twice-weekly hemodialysis is not appropriate for patients 
with renal urea clearance (Kr) <2 mL/min/1.73 m2, while 
the Work Group advised that thrice-weekly hemodialysis as 
a minimum frequency level was no longer appropriate (10). 
Based on solute kinetics, the KDOQI Work Group 
was comfortable recommending a twice-weekly dialysis 
schedule among patients with substantial RKF, defined as 
those with a Kr >3 mL/min to be initiated on twice-weekly 
hemodialysis, and those with a Kr >2 mL/min who will 
maintain this regimen (see Figure 2).
Recently, several observational studies have shown 
that twice-weekly hemodialysis is associated with better 
preservation of RKF and higher health-related quality of 
life (11,12). These findings have sparked greater interest in 
considering twice-weekly hemodialysis as an initial dialysis 
prescription. In addition, twice-weekly hemodialysis has 
demonstrated similar survival rates compared to that of 
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Figure 1 Comparing the definitions of “start” versus “transition” in order to better understand the concepts of “starting” dialysis abruptly as 
thrice-weekly hemodialysis versus incrementally “transitioning” to dialysis as twice-weekly hemodialysis (9).
Figure 2 The KDOQI guidelines pertaining to the recommended frequency of hemodialysis treatment per week based on residual kidney 
function defined by renal urea clearance (Kr) (10). 
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thrice-weekly hemodialysis among patients with substantial 
RKF (11). Given these findings, clinical practice guidelines 
allowed for the use of twice-weekly hemodialysis among 
patients with substantial RKF and have recently increased 
the weight of RKF incorporated into dialyzer Kt/V to 
calculate standard Kt/Vurea (13).
The beneficial impact of RKF on patient outcomes 
may be related to improved volume control and greater 
solute clearance, particularly that of middle molecules and 
protein-bound solutes (14,15). Traditionally, Kt/Vurea, small 
solute clearance has been the standard metric for measuring 
dialysis adequacy. However, higher dialyzer urea clearance 
(high-dose Kt/Vurea) failed to improve patient outcomes in 
the Hemodialysis (HEMO) study (16). This may be in part 
due to inadequate removal of uremic solutes other than urea 
by hemodialysis alone. Furthermore, the characteristics of 
solute clearance offered by dialysis vs. RKF are different. 
For example, protein-bound solutes are largely secreted 
by organic acid transporters in the proximal renal tubule, 
and so removed by the kidney (17). One concern regarding 
the prescription of twice-weekly hemodialysis has been 
the possibility of providing less solute clearance due to 
the longer interdialytic interval and reduced treatment 
frequency. Yet when considering the beneficial effects of 
RKF, twice-weekly hemodialysis may not be inferior in 
patients with substantial RKF compared to thrice-weekly 
hemodialysis in patients without RKF. However, from the 
viewpoint of dialysis adequacy, there are ongoing knowledge 
gaps with respect to how RKF contributes to solute 
clearance as compared with hemodialysis among patients 
receiving twice-weekly treatment.
In a recent issue of the Journal of the American Society 
of Nephrology, Leong et al. has addressed the contribution 
of RKF to the removal of secreted solutes in twice-weekly 
hemodialysis patients (18). In this study, the investigators 
measured plasma concentrations, residual renal clearance, 
and dialytic clearance for urea and secreted solutes 
including hippurate, phenylacetylglutamine, indoxyl 
sulfate, and p-cresol sulfate in nine patients with RKF 
on twice-weekly hemodialysis and nine anuric patients 
on thrice-weekly hemodialysis, respectively. Averaged 
generation rates and dialytic clearance of secreted solutes 
and urea clearance (standard Kt/Vurea) were similar in both 
groups, but the plasma concentrations of hippurate and 
phenylacetylglutamine were significantly lower in patients 
with RKF on twice-weekly hemodialysis in comparison to 
anuric patients on thrice-weekly hemodialysis. Although the 
dialytic clearances of these solutes were lower compared to 
the dialytic clearance of urea, the renal clearances of these 
solutes were significantly higher compared to the renal 
clearance of urea. On the other hand, both dialytic and renal 
clearances of indoxyl sulfate and p-cresol sulfate were lower 
compared to those of urea, probably because of the stronger 
protein-binding capacity of these solutes. Nonetheless, 
fractions of these solutes removed by renal clearance were 
still higher than that of urea removed by renal clearance. 
Interestingly, even though patients on twice-weekly 
hemodialysis had lower ultrafiltration volumes, slower 
dialysate flow rates, and shorter dialysis times per session, 
they had similar plasma levels of urea, indoxyl sulfate, and 
p-cresol sulfate, and even lower plasma levels of hippurate 
and phenylacetylglutamine compared to those on thrice-
weekly hemodialysis. 
Despite the small sample size of the study, these 
important findings reported by Leong et al. are generally 
consistent with those of previous studies and support the 
view that RKF contributes more importantly to the removal 
of secreted solutes as compared with dialysis (15,19). 
Furthermore, the authors concluded that plasma levels 
of these solutes can be well controlled by twice-weekly 
hemodialysis in patients with RKF to the same degree as 
thrice-weekly hemodialysis in anuric patients. However, 
the relative importance of RKF on clearance rates can vary 
among secreted solutes; it was greater for hippurate and 
phenylacetylglutamine than for indoxyl sulfate and p-cresol 
sulfate in this study. The variability of residual clearance 
for different secreted solutes has been observed in previous 
studies (20). This may be explained by the differential 
degree of protein binding, reduced availability for 
transporters, and biologic variability in protein expression 
of transporters among different solutes.
Although the clearance of middle molecules such as β2-
microglobulin may be enhanced by some hemodialysis 
techniques, increasing treatment adequacy or frequency of 
hemodialysis is largely limited or ineffective in improving 
the clearance of secreted solutes (16,21,22). Moreover, these 
approaches may potentially lead to more accelerated decline 
in RKF (23). Hence, preserving RKF in hemodialysis 
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patients may be more effective in removing secreted solutes 
as opposed to increasing the frequency of hemodialysis. 
Furthermore, the continuous nature of RKF, even in 
small amounts, may have a greater impact on total solute 
clearance in comparison to the intermittent nature of 
hemodialysis.
Following the study by Leong et al., it still remains 
unknown as to whether greater removal of certain secreted 
solutes by RKF among twice-weekly hemodialysis 
patients has clinical relevance. While indoxyl sulfate and 
p-cresol sulfate are among the most commonly studied 
secreted solutes in dialysis patients, in this study plasma 
concentrations of these solutes did not differ between 
patients with RKF on twice-weekly hemodialysis vs. those 
without RKF on thrice-weekly hemodialysis. Indeed, plasma 
concentrations of protein-bound solutes such as indoxyl 
sulfate and p-cresol sulfate have showed wide variation 
among patients in previous studies (15,21). Differences 
in Kt/Vurea and even in RKF accounted for little of this 
variation in plasma levels of protein-bound solutes. As 
protein-bound solutes are synthesized by the gut flora, the 
generation rates of these solutes varied considerably among 
hemodialysis patients and were not closely associated 
with RKF (15,17). In addition to the variation in solute 
generation rates, distribution volumes and the non-renal 
clearances of different solutes may also influence plasma 
concentration of secreted solutes. Subsequently, these 
factors may obscure the ability to discern the influence of 
RKF on plasma concentrations of protein-bound solutes. 
Moreover, the study by Leong et al. assessed only four 
protein-bound solutes, and thus could not assess the impact 
of RKF on other uremic solutes among patients on twice-
weekly hemodialysis. Finally, the aforementioned study 
did not assess clinical outcomes among patients with 
RKF prescribed twice-weekly hemodialysis vs. those who 
were anuric on thrice-weekly hemodialysis. In an analysis 
of the HEMO study cohort who largely had little to no 
RKF, hippurate, p-cresol sulfate, indoxyl sulfate, and 
phenylacetylglutamine concentrations were not associated 
with cardiovascular outcomes (24). However, some studies 
have suggested that uremic toxicity and adverse clinical 
outcomes may ensue from these solutes (17,25). Therefore, 
an adequately powered clinical trial is needed to determine 
whether twice-weekly hemodialysis among patients with 
higher RKF will result in greater preservation of RKF 
and improved patient outcomes beyond that of reduced 
concentrations of circulating secreted solutes. In addition, 
further studies are needed to identify adjuvant strategies 
that will best preserve residual function among patients with 
substantial RKF who initiate twice-weekly hemodialysis.
In summary, the study by Leong et al. provides reassuring 
evidence that twice-weekly hemodialysis in patients with 
RKF is associated with similar plasma concentrations of 
secreted solutes and near-equivalent dialysis adequacy as 
thrice-weekly hemodialysis in anuric patients. As discussed 
by the investigators, these results may affirm recently 
updated guidelines that have given greater weight to RKF 
in calculating total clearance and adequacy, and may also 
inspire further studies that incorporate assessment of RKF 
in the prescription of dialysis. 
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